361 related articles for article (PubMed ID: 36232447)
41. Waldenstrom macroglobulinemia with CD5+ expression presented as cryoglobulinemic glomerulonephropathy: a case report.
Kim YL; Gong SJ; Hwang YH; Joo JE; Cho YU; Lee JA; Sung SA; Lee SY; Kim NY
J Korean Med Sci; 2011 Jun; 26(6):824-8. PubMed ID: 21655071
[TBL] [Abstract][Full Text] [Related]
42. Initial Evaluation of the Patient with Waldenström Macroglobulinemia.
Castillo JJ; Treon SP
Hematol Oncol Clin North Am; 2018 Oct; 32(5):811-820. PubMed ID: 30190019
[TBL] [Abstract][Full Text] [Related]
43. [The pathology and genetic background of lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia].
Timár B
Magy Onkol; 2017 Mar; 61(1):6-11. PubMed ID: 28273183
[TBL] [Abstract][Full Text] [Related]
44. Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity.
Elsawa SF; Novak AJ; Ziesmer SC; Almada LL; Hodge LS; Grote DM; Witzig TE; Fernandez-Zapico ME; Ansell SM
Blood; 2011 Nov; 118(20):5540-9. PubMed ID: 21921047
[TBL] [Abstract][Full Text] [Related]
45. Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Talaulikar D; Tam CS; Joshua D; Ho JP; Szer J; Quach H; Spencer A; Harrison S; Mollee P; Roberts AW; Horvath N; Lee C; Zannettino A; Brown R; Augustson B; Jaksic W; Gibson J; Kalff A; Johnston A; Trotman J; Kalro A; Grigoriadis G; Ward C; Prince HM
Intern Med J; 2017 Jan; 47(1):35-49. PubMed ID: 28076910
[TBL] [Abstract][Full Text] [Related]
46. Clinical application of genomics in Waldenström macroglobulinemia.
Branagan AR; Lei M; Treon SP; Castillo JJ
Leuk Lymphoma; 2021 Aug; 62(8):1805-1815. PubMed ID: 33569985
[TBL] [Abstract][Full Text] [Related]
47. Targeted therapies in Waldenström macroglobulinemia.
Burwick N; Roccaro AM; Leleu X; Ghobrial IM
Curr Opin Investig Drugs; 2008 Jun; 9(6):631-7. PubMed ID: 18516762
[TBL] [Abstract][Full Text] [Related]
48. The role of high serum CXCL13 level in Waldenström macroglobulinemia.
Wu YY; Cai H; Zhao AL; Zhang L; Zhou DB; Cao XX; Li J
Leuk Res; 2019 Jun; 81():50-55. PubMed ID: 31015152
[TBL] [Abstract][Full Text] [Related]
49. Ibrutinib in the management of Waldenstrom macroglobulinemia.
Yosef A; Touloukian EZ; Nambudiri VE
J Oncol Pharm Pract; 2019 Mar; 25(2):434-441. PubMed ID: 29996737
[TBL] [Abstract][Full Text] [Related]
50. Waldenstrom macroglobulinemia presenting with pancreatic mass: a case report and review of literature.
Nayak HK; Kar P; Bagchi A; Kapoor N; Kapahtia S; Sonika U; Kumar N; Kumar S
JOP; 2013 Jan; 14(1):92-5. PubMed ID: 23306344
[TBL] [Abstract][Full Text] [Related]
51. Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia.
Sarosiek S; Sermer D; Branagan AR; Treon SP; Castillo JJ
Expert Rev Anticancer Ther; 2022 May; 22(5):471-478. PubMed ID: 35404729
[TBL] [Abstract][Full Text] [Related]
52. Pharmacokinetics-Pharmacodynamics Modeling and Evaluation of Tumor Response to Bortezomib Proteasome Inhibitor in Waldenstrom Macroglobulinemia.
Munir A; Fazal S; Bhatti AI; Sajjad B
Am J Clin Oncol; 2023 Apr; 46(4):150-160. PubMed ID: 36808095
[TBL] [Abstract][Full Text] [Related]
53. Genomic abnormalities of Waldenström macroglobulinemia and related low-grade B-cell lymphomas.
Braggio E; Fonseca R
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):198-201. PubMed ID: 23477936
[TBL] [Abstract][Full Text] [Related]
54. A case of anaplastic large cell (Ki-1) lymphoma of B-cell phenotype, occurring in Waldenström's macroglobulinemia.
Hamada T; Ishizuka H; Asai Y; Yamazaki T; Sawada U; Hasegawa H; Uchida T
Pathol Int; 1999 Oct; 49(10):913-7. PubMed ID: 10571827
[TBL] [Abstract][Full Text] [Related]
55. Assessment of bone marrow response in Waldenström's macroglobulinemia.
Varghese AM; Rawstron AC; Ashcroft AJ; Moreton P; Owen RG
Clin Lymphoma Myeloma; 2009 Mar; 9(1):53-5. PubMed ID: 19362973
[TBL] [Abstract][Full Text] [Related]
56. An unusual case of cutaneous Waldenström macroglobulinemia with the MYD88 L265P mutation.
Minzenmayer AN; Miranda RN; Powell PR; Parekh PK
J Cutan Pathol; 2020 Sep; 47(9):850-853. PubMed ID: 32335928
[TBL] [Abstract][Full Text] [Related]
57. Extramedullary Waldenström macroglobulinemia.
Banwait R; Aljawai Y; Cappuccio J; McDiarmid S; Morgan EA; Leblebjian H; Roccaro AM; Laubach J; Castillo JJ; Paba-Prada C; Treon S; Redd R; Weller E; Ghobrial IM
Am J Hematol; 2015 Feb; 90(2):100-4. PubMed ID: 25349134
[TBL] [Abstract][Full Text] [Related]
58. Kidney diseases associated with Waldenström macroglobulinemia.
Uppal NN; Monga D; Vernace MA; Mehtabdin K; Shah HH; Bijol V; Jhaveri KD
Nephrol Dial Transplant; 2019 Oct; 34(10):1644-1652. PubMed ID: 30380110
[TBL] [Abstract][Full Text] [Related]
59. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Kumar SK; Callander NS; Adekola K; Anderson LD; Baljevic M; Baz R; Campagnaro E; Castillo JJ; Costello C; D'Angelo C; Derman B; Devarakonda S; Elsedawy N; Garfall A; Godby K; Hillengass J; Holmberg L; Htut M; Huff CA; Hultcrantz M; Kang Y; Larson S; Lee H; Liedtke M; Martin T; Omel J; Robinson T; Rosenberg A; Sborov D; Schroeder MA; Sherbenou D; Suvannasankha A; Valent J; Varshavsky-Yanovsky AN; Snedeker J; Kumar R
J Natl Compr Canc Netw; 2024 Jan; 22(1D):e240001. PubMed ID: 38244272
[TBL] [Abstract][Full Text] [Related]
60. Monoclonal Antibodies for Waldenström Macroglobulinemia.
Dominguez A; Kastritis E; Castillo JJ
Hematol Oncol Clin North Am; 2018 Oct; 32(5):841-852. PubMed ID: 30190022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
